Deal

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquires MPI Research

April 2018 full acquisition ready

Snapshot

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired MPI Research for approximately $800 million in cash in April 2018. The transaction was structured as all cash. MPI Research is a United States (Mattawan, Michigan)-based Discovery and Safety Assessment (DSA) business.

Acquirer
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Target
MPI Research
Value
approximately $800 million in cash
Date
April 2018
Type
full acquisition
Status
ready
01 Scorecard

The deal at a glance

Private-market deal
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquires MPI Research
Deal value
approximately $800 million in cash
Sector
Discovery and Safety Assessment (DSA)
Date
April 2018
VectorShift
Made on VectorShift

About this deal

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired MPI Research for approximately $800 million in cash, a transaction completed in April 2018, structured as all cash.

MPI Research operates in Discovery and Safety Assessment (DSA), is based in United States (Mattawan, Michigan). MPI Research was a premier non-clinical contract research organization providing safety assessment, discovery, and bioanalytical services, with a large site in Mattawan, Michigan.

Acquiring MPI will enhance Charles River's position as a leading global early-stage CRO by strengthening its ability to partner with clients across the drug discovery and development continuum.

Access to growing end markets, high-quality services, scientific expertise, and complementary capabilities Expected non-GAAP EPS accretion of approximately $0.25 in 2018 and approximately $0.60 in 2019 Discovery and Safety Assessment (DSA) segment

In addition to meeting our disciplined acquisition criteria, MPI is an exceptional strategic fit for Charles River because it incorporates the key attributes we require in an acquisition: access to growing end markets, high-quality services, scientific expertise, and complementary capabilities.
James C. Foster, Chairman and Chief Executive Officer, Charles River Laboratories
We believe that the acquisition of MPI will generate value for shareholders, driving profitable revenue growth and non-GAAP earnings per share accretion of approximately $0.25 in 2018 and approximately $0.60 in 2019.
James C. Foster, Chairman and Chief Executive Officer, Charles River Laboratories
Advisors not disclosed

No advisory firms have been disclosed for this transaction.

Sources Press releaseSEC filing Last updated

See how VectorShift works for your firm

Request Demo